Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis

Area of Science:

• Neurology
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) is a prevalent condition among male patients diagnosed with multiple sclerosis (MS).
• Sildenafil citrate is a widely used treatment for ED in the general population, yet its effectiveness in MS patients requires systematic evaluation.

Purpose of the Study:

• To systematically assess the efficacy and safety of sildenafil citrate for treating erectile dysfunction (ED) specifically in patients with multiple sclerosis (MS).

Main Methods:

• Conducted a systematic review of randomized controlled trials (RCTs) comparing sildenafil citrate with placebo for ED in MS patients.
• Searched multiple databases including Cochrane, MEDLINE, EMBASE, and CBM up to November 2011.
• Extracted data and assessed trial quality independently, resolving disagreements through discussion.

Main Results:

• Two RCTs involving 420 patients indicated that sildenafil citrate improved erectile function (IIEF, Sexual Encounter Profile) and global response (Global Assessment Question) compared to placebo.
• One study suggested benefits in quality of life, while the other found no significant difference.
• Common adverse events included headache and flushing; serious events involved coronary artery disease and cerebrovascular accident.

Conclusions:

• Limited evidence currently supports sildenafil citrate for ED in MS patients.
• High-quality, well-designed, long-term randomized, double-blind, placebo-controlled trials are necessary to establish definitive efficacy and safety.